Canadian MASLD Network

@GiadaSebastiani @Felice_Cinque @CIHR_CTN @CASLupdates @FRQS1 @IDIGHProgram @McGill_DOM @RIMUHC1 @cusm_muhc @TheLancetHIV Congratulations!

✨My new publication in The Lancet HIV✨ ✅ #MASLD affects 26-40% of people with #HIV ✅ We advocate for the integration of non-invasive screening, lifestyle interventions and holistic strategies into HIV care, to promote healthy aging in this population thelancet.com/journals/lanhi…

MASLD affects 1/3 of the global adult population, driven in part by poor dietary habits. In honor of #worldliverday this Saturday, get to know your liver and how to keep it happy using great resources at worldliverday.org

Carmela's research examines the prognostic value of steatotic liver disease classifications in association with all-cause mortality, with a focus on sex differences.

👏🎉Congratulations🎉👏 to @carmela_rapino, the inaugural Canadian MASLD Network Research Fellow, who was just awarded the Canadian Graduate Scholarship from @CIHR_IRSC! Carmela is supervised by Dr. @GiadaSebastiani and Dr. @SaharZSaeed at @queensu.

The new open access issue of Canadian Liver Journal includes abstracts from the Annual Canadian Liver Meeting 2025! Read more: bit.ly/CNLJ81l Join us this weekend at #CDDWCLM2025! @cddw_clm @CASLupdates @CanMASLDNetwork @canhepc

🚨Pleased to coauthor this new publication🚨 ➡️In patients with type 2 #diabetes in UK, SGLT-2 inhibitors were associated with a lower risk of #cirrhosis compared to DPP-4 inhibitors ➡️ #GLP1 RAs were not associated with a lower risk of cirrhosis 👉diabetesjournals.org/care/article-a…

🚨Pleased to coauthor this new publication in @AmJGastro🚨 ✳️Global rise in liver cancer attributable to metabolic risks observed from 1990 to 2021 ✳️High #BMI identified as the major contributing risk factor #MASLD #HCC #diabetes #obesity #livertwitter journals.lww.com/ajg/abstract/9…

🌟😊Proud of my trainee Dana receiving the Raymond T. Chung Emerging Liver Scholar award! 🎉Sharing this achievement for Canadian #hepatology with Carla Coffin, #President of Canadian Association for the Study of the #Liver @CASLupdates #TLM2024 @AASLDtweets @AASLDFoundation

🌟Honoured to speak at the #Montreal Gala for Crohn's Colitis Canada, grateful for their support to my research! 🟢As the #President Elect of the Canadian #Liver Association, our partnership advance research for people with #IBD and related liver conditions. #MASLD #LiverTwitter

We are keeping up with the times -- Excited to announce our renaming to the Canadian MASLD Network! Our website has moved too! ➡️canmasld.org

Have a listen to CanNASH member Dr. Mark Swain and Dr. Alberta Tsui with Alberta Precision Labs / UAlberta discuss liver fibrosis and the FIB-4 test on the @CSCC_CACB Lab Report Podcast ➡️ cscc-sccc.ca/education-scie…

Very exciting event happening in Vancouver through a fantastic collaboration between CanNASH and @FattyLiverA. Thanks to CanNASH member Dr. Alnoor Ramji for talking to his community about liver health!

🚨 Call for Abstracts! Got groundbreaking research or innovative ideas? Now is your chance to submit your abstract to be part of #CDDWCLM2025. Don't miss this opportunity! Visit cddw-clm.ca to learn more✨ #Research #Gastroenterology #Hepatology #CallForAbstracts

Thrilled to contribute to knowledge dissemination for primary care physicians! 🟢Practical insights on how to navigate the complexities of #MASLD in everyday practice 🟠Making #screening and management more approachable #communautéFRQ #LiverTwitter 👉doi.org/10.58931/cpct.…

CanNASH is represented at the @GlobalLiver #a3experience event in Washington, DC! Thanks to Mike from the @FattyLiverA for this amazing opportunity to learn from patients sharing their stories!

In today's fireside chat , Michael Betel, President and Founder of the Fatty Liver Alliance, and Professor @GiadaSebastiani, Hepatologist at @mcgillu, explore the comprehensive management of fatty liver disease, now termed MASLD, and reflect on her recently published perspective paper, "Integrating behavioral interventions into a holistic approach to metabolic dysfunction-associated steatotic liver disease". Giada Sebastiani emphasized the necessity of a holistic, multidisciplinary approach to treating MASLD, acknowledging the complexity of the disease that affects multiple systems beyond the liver. She highlighted the recent approval of Rezdiffra for treating MASH in the U.S., which should be complemented with lifestyle changes such as diet and exercise. Dr. Sebastiani underscored that while pharmacological solutions are crucial, they must be integrated with behavioral interventions and lifestyle modifications to be truly effective. Here are the three key takeaways from the discussion: 1. Holistic and Multidisciplinary Approach: Effective management of MASLD requires a comprehensive approach that integrates pharmacological treatments with lifestyle modifications such as diet, exercise, and behavioral interventions. Addressing the disease's multifaceted nature, which affects multiple systems beyond the liver, is essential for improving patient outcomes. 2. Early Intervention and Personalized Care: Early intervention targeting upstream issues like obesity, type 2 diabetes, and eating disorders is crucial in preventing the progression of MASLD. Personalized care tailored to individual patient characteristics enhances the effectiveness of treatment and promotes better health outcomes. 3. Patient Education and Advocacy: Empowering patients with knowledge about MASLD and available treatment options is vital for enabling informed decision-making and encouraging early diagnosis and intervention. Increased awareness and advocacy efforts are essential for improving the management of MASLD and supporting affected individuals. Link to blog with video: fattyliver.ca/blog/f/masld-p… @livertwitter @liverX

In March 2024 @AASLDtweets announced the selection of sixty-two #hepatology leaders as Fellows and one allied #healthleader focused on hepatology as an Associate Fellow. Congratulations to #CASLMembers @cscoffin, @GiadaSebastiani, and Hin Hin Ko! 👏 aasld.org/aasld-announce…

✅Our new paper on #sex differences for #MASLD in people with #HIV! 🟩Lower prevalence of MASLD with #fibrosis in #women than men 🟥Women reach similar levels of liver disease at the perimenopausal age 👉doi.org/10.1111/hiv.13… @CIHR_CTN @McGill_DOM @CASLupdates @HIV_Medicine

*⃣Pleased to coauthor this viewpoint on #resmetirom and #MASLD with the Global #Obesity Collaborative 🟩Focus on a comprehensive treatment for #metabolic health 👉link.springer.com/article/10.100… @McGill_DOM @CASLupdates @SpringerNature @FRQS1 @RIMUHC1 @cusm_muhc @ObesityCan @rrcmdo